《大行》摩通降康方生物(09926.HK)目标价至99元 料美国监管存不确定性

阿斯达克财经
Jun 04, 2025

摩根大通发表研究报告指,康方生物(09926.HK) 周一(2日)股价下跌约10%,而同日恒指仅跌约0.5%,相信是由于Summit Therapeutics(SMMT.US)  日前公布依沃西单抗全球三期临床试验HARMONi研究顶线结果,透露产品在美国提交生物制剂许可申请的时间表尚未明确,增加市场对美国监管不确定性的担忧。摩通将依沃西单抗在美国的成功上市概率预测下调约10%,该产品于2026至...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10